Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in HR-positive breast cancer after palbociclib progression (phase II, single-arm)
ChiCTR2200061151Phase 2Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: objective response rate. Started Sep 2022; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200061151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061151.